Abstract
The treatment of multiple myeloma has changed dramatically in the last decade with the introduction of thalidomide, bortezomib, and lenalidomide. Patients eligible for autologous stem cell transplantation (ASCT) are treated with non-alkylating agent-containing regimens as initial therapy; typically thalidomide-dexamethasone or lenalidomide-dexamethasone. For patients not eligible for ASCT, the current standard of care is melphalan, prednisone, and thalidomide. Ongoing trials will soon assess if combinations including melphalan and prednisone plus bortezomib or MP plus lenalidomide may be considered an attractive option. Patients who have risk factors, such as deletion 13 or translocation t(4;14) or t(14;16), are candidates for novel, more aggressive treatments.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1141-1156 |
| Number of pages | 16 |
| Journal | Hematology/Oncology Clinics of North America |
| Volume | 21 |
| Issue number | 6 |
| DOIs | |
| State | Published - Dec 2007 |
Fingerprint
ASJC Scopus subject areas
- Oncology
- Hematology
Cite this
Management of Newly Diagnosed Myeloma. / Rajkumar, S Vincent; Palumbo, Antonio.
In: Hematology/Oncology Clinics of North America, Vol. 21, No. 6, 12.2007, p. 1141-1156.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Management of Newly Diagnosed Myeloma
AU - Rajkumar, S Vincent
AU - Palumbo, Antonio
PY - 2007/12
Y1 - 2007/12
N2 - The treatment of multiple myeloma has changed dramatically in the last decade with the introduction of thalidomide, bortezomib, and lenalidomide. Patients eligible for autologous stem cell transplantation (ASCT) are treated with non-alkylating agent-containing regimens as initial therapy; typically thalidomide-dexamethasone or lenalidomide-dexamethasone. For patients not eligible for ASCT, the current standard of care is melphalan, prednisone, and thalidomide. Ongoing trials will soon assess if combinations including melphalan and prednisone plus bortezomib or MP plus lenalidomide may be considered an attractive option. Patients who have risk factors, such as deletion 13 or translocation t(4;14) or t(14;16), are candidates for novel, more aggressive treatments.
AB - The treatment of multiple myeloma has changed dramatically in the last decade with the introduction of thalidomide, bortezomib, and lenalidomide. Patients eligible for autologous stem cell transplantation (ASCT) are treated with non-alkylating agent-containing regimens as initial therapy; typically thalidomide-dexamethasone or lenalidomide-dexamethasone. For patients not eligible for ASCT, the current standard of care is melphalan, prednisone, and thalidomide. Ongoing trials will soon assess if combinations including melphalan and prednisone plus bortezomib or MP plus lenalidomide may be considered an attractive option. Patients who have risk factors, such as deletion 13 or translocation t(4;14) or t(14;16), are candidates for novel, more aggressive treatments.
UR - http://www.scopus.com/inward/record.url?scp=35748974554&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=35748974554&partnerID=8YFLogxK
U2 - 10.1016/j.hoc.2007.08.008
DO - 10.1016/j.hoc.2007.08.008
M3 - Article
C2 - 17996592
AN - SCOPUS:35748974554
VL - 21
SP - 1141
EP - 1156
JO - Hematology/Oncology Clinics of North America
JF - Hematology/Oncology Clinics of North America
SN - 0889-8588
IS - 6
ER -